Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
MCL1 is essential for the survival of stem and progenitor cells of multiple lineages, and is unique among pro-survival BCL2 family members in that it is rapidly turned over through the action of ubiquitin ligases. B- and mantle-cell lymphomas, chronic myeloid leukaemia, and multiple myeloma, however, express abnormally high levels of MCL1, contributing to chemoresistance and disease relapse. The mechanism of MCL1 overexpression in cancer is not well understood. Here we show that the deubiquitinase USP9X stabilizes MCL1 and thereby promotes cell survival. USP9X binds MCL1 and removes the Lys 48-linked polyubiquitin chains that normally mark MCL1 for proteasomal degradation. Increased USP9X expression correlates with increased MCL1 protein in human follicular lymphomas and diffuse large B-cell lymphomas. Moreover, patients with multiple myeloma overexpressing USP9X have a poor prognosis. Knockdown of USP9X increases MCL1 polyubiquitination, which enhances MCL1 turnover and cell killing by the BH3 mimetic ABT-737. These results identify USP9X as a prognostic and therapeutic target, and they show that deubiquitinases may stabilize labile oncoproteins in human malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phosphorylation of MCL1 at S159 and T163 also affects the USP9X-MCL1 interaction [121].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [121]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
Self-citationThe molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T. F. E., Bernd, H.-W., Cogliatti, S. B., Dierlamm, J., Feller, A. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055351 · Cited by 1,006
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
Zhong, Q., Gao, W., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.06.009 · Cited by 842
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801
Cited by
Items 201–300 of 630
Wnt modulates MCL1 to control cell survival in triple negative breast cancer
Yang, L., Perez, A. A., Fujie, S., Warden, C., Li, J., Wang, Y., Yung, B. S., Chen, Y.-R., Liu, X., Zhang, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-124 · Cited by 74
Song, J. H., & Kraft, A. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-3240 · Cited by 70
Deubiquitinase USP9X deubiquitinates β-catenin and promotes high grade glioma cell growth
Yang, B., Zhang, S., Wang, Z., Yang, C., Ouyang, W., Zhou, F., Zhou, Y., & Xie, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12819 · Cited by 62
Spinella, J.-F., Cassart, P., Richer, C., Saillour, V., Ouimet, M., Langlois, S., St-Onge, P., Sontag, T., Healy, J., Minden, M. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11796 · Cited by 68
Zhu, C., Ji, X., Zhang, H., Zhou, Q., Cao, X., Tang, M., Si, Y., Yan, H., Li, L., Liang, T., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000392 · Cited by 66
Guo, Y., Dolinko, A. V., Chinyengetere, F., Stanton, B. A., Bomberger, J. M., Demidenko, E., Zhou, D.-C., Gallagher, R. E., Ma, T., Galimberti, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1100 · Cited by 65
Liu, Y., Xu, X., Lin, P., He, Y., Zhang, Y., Cao, B., Zhang, Z., Sethi, G., Liu, J., Zhou, X., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006057 · Cited by 59
Self-citationAgrawal, P., Chen, Y., Schilling, B., Gibson, B. W., & Hughes, R. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.328021 · Cited by 66
The peroxisomal receptor dislocation pathway: To the exportomer and beyond
Platta, H. W., Hagen, S., Reidick, C., & Erdmann, R. (2013) · Biochimie · doi:10.1016/j.biochi.2013.12.009 · Cited by 68
Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication
Tsai, Y. C., Kotiya, A., Kiris, E., Yang, M., Bavari, S., Tessarollo, L., Oyler, G. A., & Weissman, A. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621076114 · Cited by 60
Park, Y., Jin, H., & Liu, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221925110 · Cited by 63
Karpel‐Massler, G., Ramani, D., Shu, C., Halatsch, M., Westhoff, M., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9257 · Cited by 64
USP14 activation promotes tumor progression in hepatocellular carcinoma
Huang, G., Li, L., & Zhou, W. (2015) · Oncology Reports · doi:10.3892/or.2015.4296 · Cited by 61
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications
Fulda, S., Rajalingam, K., & Đikić, I. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100707 · Cited by 76
Dual modulation of MCL-1 and mTOR determines the response to sunitinib
Elgendy, M., Abdel-Aziz, A. K., Renne, S. L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C. K., Bossi, D., Pallavicini, I., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84386 · Cited by 57
Zhang, C., Cai, T., Zhu, H., Yang, L., Jiang, H., Dong, X., Hu, Y., Lin, N.-M., He, Q., & Yang, B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1091 · Cited by 58
Kang, X.-H., Zhang, J.-H., Zhang, Q.-Q., Cui, Y.-H., Wang, Y., Kou, W.-Z., Miao, Z.-H., Lu, P., Wang, L.-F., Xu, Z.-Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475438 · Cited by 55
Luo, Q., Wu, X., Nan, Y., Chang, W., Zhao, P., Zhang, Y., Su, D., & Liu, Z. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.017 · Cited by 60
Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system
Chen, L. S., Balakrishnan, K., & Gandhi, V. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.039 · Cited by 55
“Finally Mcl-1 has a selective ubiquitinating and deubiquitinating enzymes, MULE [106] and USP9X [107] respectively.”
BackgroundBRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells
He, K., Chen, D., Ruan, H., Li, X., Tong, J., Xu, X. M., Zhang, L., & Yu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10277 · Cited by 61
An RNAi screen identifies USP2 as a factor required for TNF‐α‐induced NF‐κB signaling
Metzig, M. O., Nickles, D., Falschlehner, C., Lehmann‐Koch, J., Straub, B. K., Roth, W., & Boutros, M. (2011) · International Journal of Cancer · doi:10.1002/ijc.26124 · Cited by 59
PDK1 regulates B cell differentiation and homeostasis
Baracho, G. V., Cato, M. H., Zhu, Z., Jaren, O. R., Hobeika, E., Reth, M. G., & Rickert, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314562111 · Cited by 55
Role of Angiomotin‐like 2 mono‐ubiquitination on YAP inhibition
Kim, M., Kim, M., Park, S., Lee, C., & Lim, D. (2015) · EMBO Reports · doi:10.15252/embr.201540809 · Cited by 60
miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer
Chen, J., Chen, Y., & Chen, Z. (2013) · Cancer Investigation · doi:10.3109/07357907.2012.743557 · Cited by 56
Deubiquitinating enzymes in cancer stem cells: functions and targeted inhibition for cancer therapy
Kaushal, K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.035 · Cited by 60
Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system
Moran-Crusio, K., Reavie, L., & Aifantis, I. (2012) · Trends in immunology · doi:10.1016/j.it.2012.01.009 · Cited by 54
Liu, H., Yang, J., Yuan, Y., Xia, Z., Chen, M., Xie, L., Ma, X., Wang, J., Ouyang, S., Wu, Q., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-98 · Cited by 63
Molecular Pathways: Translational Potential of Deubiquitinases as Drug Targets
D’Arcy, P., & Linder, S. T. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0568 · Cited by 56
Barillé‐Nion, S., Bah, N. K., Véquaud, É., & Juin, P. P. (2012) · PubMed · Cited by 61
McGarry, E., Gaboriau, D. C. A., Rainey, M. D., Restuccia, U., Bachi, A., & Santocanale, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2890 · Cited by 58
Kirschnek, S., Vier, J., Gautam, S., Frankenberg, T., Rangelova, S., Eitz-Ferrer, P., Grespi, F., Ottina, E., Villunger, A., Häcker, H., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.69 · Cited by 60
Shostak, K., Jiang, Z., Charloteaux, B., Mayer, A., Habraken, Y., Tharun, L., Klein, S., Xu, X., Duong, H. Q., Vislovukh, A. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15003-7 · Cited by 57
Karpel‐Massler, G., Shu, C., Chau, L., Banu, M. A., Halatsch, M., Westhoff, M., Ramirez, Y. P., Ross, A. H., Bruce, J. N., Canoll, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3993 · Cited by 55
Ubiquitin-Specific Proteases as Cancer Drug Targets
Sippl, W., Collura, V., & Colland, F. (2011) · Future Oncology · doi:10.2217/fon.11.39 · Cited by 55
The deubiquitinase Usp27x stabilizes the BH3‐only protein Bim and enhances apoptosis
Weber, A., Heinlein, M., Dengjel, J., Alber, C., Singh, P. K., & Häcker, G. A. (2016) · EMBO Reports · doi:10.15252/embr.201541392 · Cited by 63
The exportomer: the peroxisomal receptor export machinery
Platta, H. W., Hagen, S., & Erdmann, R. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1136-9 · Cited by 62
Myeloid nuclear differentiation antigen, neutrophil apoptosis and sepsis
Milot, É., Fotouhi‐Ardakani, N., & Filep, J. G. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00397 · Cited by 56
USP9X Deubiquitylates DVL2 to Regulate WNT Pathway Specification
Nielsen, C. P., Jernigan, K. K., Diggins, N. L., Webb, D. J., & MacGurn, J. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.083 · Cited by 56
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 67
Vogel, R. I., Coughlin, K. A., Scotti, A., Iizuka, Y., Anchoori, R. K., Roden, R. B. S., Marastoni, M., & Bazzaro, M. (2015) · Oncotarget · doi:10.18632/oncotarget.2904 · Cited by 54
Kapoor, S., Natarajan, K., Baldwin, P. R., Doshi, K. A., Lapidus, R. G., Mathias, T. J., Scarpa, M., Trotta, R., Dávila, E., Kraus, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1629 · Cited by 51
Qian, Y., Wang, B., Ma, A., Zhang, L., Xu, G., Ding, Q., Jing, T., Wu, L., Liu, Y., Yang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep33039 · Cited by 51
Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer
Pal, A., & Donato, N. J. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0461-3 · Cited by 56
Usp12 stabilizes the T-cell receptor complex at the cell surface during signaling
Jahan, A. S., Lestra, M., Swee, L. K., Fan, Y., Lamers, M. M., Tafesse, F., Theile, C. S., Spooner, E., Bruzzone, R., Ploegh, H. L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521763113 · Cited by 58
Mcl‐1 targeting could be an intriguing perspective to cure cancer
Blasio, A. D., Vento, R., & Fiore, R. D. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26786 · Cited by 59
BAG1: The Guardian of Anti-Apoptotic Proteins in Acute Myeloid Leukemia
Aveic, S., Pigazzi, M., & Basso, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026097 · Cited by 55
Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma
Karpel‐Massler, G., Ishida, C. T., Zhang, Y., Halatsch, M., Westhoff, M., & Siegelin, M. D. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356286 · Cited by 51
The roles of ubiquitin modifying enzymes in neoplastic disease
Kumari, N., Jaynes, P. W., Saei, A., Iyengar, P. V., Richard, J. L. C., & Eichhorn, P. J. A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.002 · Cited by 52
Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy
Kelly, G. L., & Strasser, A. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033510 · Cited by 55
Nifoussi, S. K., Vrana, J. A., Domina, A. M., Biasio, A. D., Gui, J., Gregory, M. A., Hann, S., & Craig, R. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047060 · Cited by 53
Wang, R., Xia, L., Gabrilove, J. L., Waxman, S., & Jing, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0663 · Cited by 51
Targeting Cell Survival Proteins for Cancer Cell Death
Pandey, M. K., Prasad, S., Tyagi, A. K., Deb, L., Huang, J. M., Karelia, D. N., Amin, S., & Aggarwal, B. B. (2016) · Pharmaceuticals · doi:10.3390/ph9010011 · Cited by 57
Lian, J., Ni, Z., Dai, X., Su, C., Smith, A. R., Xu, L., & He, F. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0559 · Cited by 47
Bridges, C. R., Tan, M. C., Premarathne, S., Nanayakkara, D. M., Bellette, B., Zencak, D., Domingo, D., Gécz, J., Murtaza, M., Jolly, L. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00149-0 · Cited by 45
FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation
Feng, C., Yang, F., & Wang, J. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.24 · Cited by 50
Chen, E., Li, E., Liu, H., Zhou, Y., Wen, L., Wang, J., Wang, Y., Ye, L., & Liang, T. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.52517 · Cited by 49
Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis
Simonin, K., N’Diaye, M., Lheureux, S., Loussouarn, C., Dutoit, S., Briand, M., Giffard, F., Brotin, É., Blanc‐Fournier, C., & Poulain, L. (2013) · APOPTOSIS · doi:10.1007/s10495-012-0799-x · Cited by 46
Okamoto, T., Coultas, L., Metcalf, D., van Delft, M. F., Glaser, S. P., Takiguchi, M., Strasser, A., Bouillet, P., Adams, J. M., & Huang, D. C. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321259110 · Cited by 46
Self-citationKapuria, V., Peterson, L. F., Showalter, H. D., Kirchhoff, P. D., Talpaz, M., & Donato, N. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.012 · Cited by 52
USP9X Downregulation Renders Breast Cancer Cells Resistant to Tamoxifen
Oosterkamp, H. M., Hijmans, E. M., Brummelkamp, T. R., Canisius, S., Wessels, L. F. A., Zwart, W. T., & Bernards, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1960 · Cited by 49
Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma
Zhang, F.-K., Ni, Q., Wang, K., Cao, H., Guan, D., Zhang, E., Ma, N., Wang, Y., Zheng, Q., Xu, S., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.03.009 · Cited by 48
Deubiquitinases as novel therapeutic targets for diseases
Xian, Y., Ye, J., Tang, Y., Zhang, N., Peng, C. Y., Huang, W., & He, G. (2024) · MedComm · doi:10.1002/mco2.70036 · Cited by 69
Varadarajan, S., Poornima, P., Milani, M., Gowda, K., Amin, S., Wang, H., & Cohen, G. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3706 · Cited by 51
Genetic disruption ofUSP9Xsensitizes colorectal cancer cells to 5-fluorouracil
Harris, D. R., Pike, A. M., & Bunz, F. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21792 · Cited by 48
Campone, M., Noël, B., Couriaud, C., Grau, M., Guillemin, Y., Gautier, F., Gouraud, W., Guérin‐Charbonnel, C., Campion, L., Jézéquel, P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-110 · Cited by 55
Habata, S., Iwasaki, M., 杉尾, 明., Suzuki, M., Tamate, M., Satohisa, S., Tanaka, R., & Saito, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3494 · Cited by 49
Small-Molecule Suppressors of Cytokine-Induced β-Cell Apoptosis
Chou, D. H., Bodycombe, N. E., Carrinski, H. A., Lewis, T. A., Clemons, P. A., Schreiber, S. L., & Wagner, B. K. (2010) · ACS Chemical Biology · doi:10.1021/cb100129d · Cited by 52
Chen, D. Y., Liu, H., Takeda, S., Tu, H.-C., Sasagawa, S., Tine, B. A. V., Lu, D., Cheng, E. H. Y., & Hsieh, J. J.-D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0027 · Cited by 51
Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 46
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Lill, J. R., & Wertz, I. E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.005 · Cited by 52
Self-citationVogel, R. I., Pulver, T., Heilmann, W., Mooneyham, A., Mullany, S. A., Zhao, X., Shahi, M., Richter, J., Klein, M. E., Chen, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8821 · Cited by 44
The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability
Yang, W.-C., & Shih, H.-M. (2012) · Oncogene · doi:10.1038/onc.2012.537 · Cited by 49
OTUD4: A Potential Prognosis Biomarker for Multiple Human Cancers
Zhao, X., Su, X., Cao, L., Xie, T., Chen, Q., Li, J., Xu, R., & Jiang, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s233028 · Cited by 42
USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines
Wang, H., Meng, Q., Ding, Y., Xiong, M., Zhu, M., Yang, Y., Su, H., Gu, L., Xu, Y., Li, S., et al. (2020) · FEBS Journal · doi:10.1111/febs.15461 · Cited by 43
Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer
Yu, X., Zhou, L. Q., Liu, W., Liu, L., Gao, F., Li, W., & Liu, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04685-0 · Cited by 46
MicroRNA-29b is a Novel Prognostic Marker in Colorectal Cancer
Inoue, A., Yamamoto, H., Uemura, M., Nishimura, J., Hata, T., Takemasa, I., Ikenaga, M., Ikeda, M., Murata, K., Mizushima, T., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4255-8 · Cited by 45
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination
Kapuria, V., Levitzki, A., Bornmann, W. G., Maxwell, D. S., Priebe, W., Sorenson, R. J., Showalter, H. D., Talpaz, M., & Donato, N. J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.002 · Cited by 47
Deubiquitinating Enzymes Related to Autophagy: New Therapeutic Opportunities?
Jacomin, A., Taillebourg, E., & Fauvarque, M. (2018) · Cells · doi:10.3390/cells7080112 · Cited by 45
TGF-β signaling pathway mediated by deubiquitinating enzymes
Kim, S., & Baek, K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2949-y · Cited by 48
Post-translational Modifications (PTMs), from a Cancer Perspective: An Overview
Sharma, B. S., Prabhakaran, V., Desai, A. P., Bajpai, J., Verma, R. J., & Swain, P. K. (2019) · Oncogen · doi:10.35702/onc.10012 · Cited by 49
USP9X stabilizes BRCA1 and confers resistance to DNA‐damaging agents in human cancer cells
Lu, Q., Zhang, F.-L., Lu, D., Shao, Z., & Li, D. (2019) · Cancer Medicine · doi:10.1002/cam4.2528 · Cited by 45
Mitochondrial apoptosis and BH3 mimetics
Dai, H., Meng, X. W., & Kaufmann, S. H. (2016) · F1000Research · doi:10.12688/f1000research.9629.1 · Cited by 50
The role of deubiquitinases in breast cancer
Xiao, Z., Zhang, P., & Ma, L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9640-2 · Cited by 43
Nguyen, T., Andrējeva, D., Gupta, R., Choudhary, C., Hong, X., Eichhorn, P. J. A., Loya, A. C., & Cohen, S. M. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.1 · Cited by 43
The deubiquitylase USP9X controls ribosomal stalling
Clancy, A., Heride, C., Pinto-Fernández, A., Elcocks, H., Kallinos, A., Kayser-Bricker, K. J., Wang, W., Smith, V., Davis, S. A., Fessler, S. P., et al. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202004211 · Cited by 48
Wang, Y., Xie, Q., Tan, H., Liao, M., Zhu, S., Zheng, L., Huang, H., & Liu, B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105702 · Cited by 44
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Vichas, A., Riley, A. K., Nkinsi, N. T., Kamlapurkar, S., Parrish, P. C. R., Lo, A., Duke, F. F., Chen, J., Fung, I., Watson, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24841-y · Cited by 48
Sox2: regulation of expression and contribution to brain tumors
Mansouri, S., Nejad, R., Karabork, M., Ekinci, C., Solaroğlu, İ., Aldape, K., & Zadeh, G. M. (2016) · CNS Oncology · doi:10.2217/cns-2016-0001 · Cited by 48
Carneiro, A. P., Reis, C. F., Morari, E. C., Maia, Y. C. D. P., Nascimento, R., Bonatto, J. M. C., de Souza, M. A., Goulart, L. R., & Ward, L. S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.331 · Cited by 40
Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma
Laetsch, T. W., Liu, X., Vu, A. T., Sliozberg, M., Vido, M. J., Elci, O. U., Goldsmith, K. C., & Hogarty, M. D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.40 · Cited by 40
HUWE1 and TRIP12 Collaborate in Degradation of Ubiquitin-Fusion Proteins and Misframed Ubiquitin
Poulsen, E. G., Steinhauer, C., Lees, M. J., Lauridsen, A.-M. B., Ellgaard, L., & Hartmann‐Petersen, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050548 · Cited by 44
Cross Talk of Proteostasis and Mitostasis in Cellular Homeodynamics, Ageing, and Disease
Gumeni, S., & Trougakos, I. P. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4587691 · Cited by 48
Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo
Karpel‐Massler, G., Banu, M. A., Shu, C., Halatsch, M., Westhoff, M., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2016) · Oncotarget · doi:10.18632/oncotarget.7302 · Cited by 40
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Al‐Odat, O. S., Suskil, M. V., Chitren, R. J., Elbezanti, W. O., Srivastava, S. K., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Aggarwal, B. B., & Pandey, M. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.699629 · Cited by 45
Bcl-2 antagonists: a proof of concept for CLL therapy
Balakrishnan, K., & Gandhi, V. V. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0002-4 · Cited by 42
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies
Khaw, S. L., Huang, D. C. S., & Roberts, A. W. (2011) · Pathology · doi:10.1097/pat.0b013e32834b1b34 · Cited by 43
Self-citationInhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds
Liu, N., Huang, H., Dou, Q. P., & Liu, J. (2015) · Oncoscience · doi:10.18632/oncoscience.167 · Cited by 44
Self-citationNarayanan, N., Wang, Z., Li, L., & Yang, Y. (2017) · Cell Discovery · doi:10.1038/celldisc.2016.48 · Cited by 39
Pal, A., Dziubinski, M., Di Magliano, M. P., Simeone, D. M., Owens, S., Thomas, D., Peterson, L., Potu, H., Talpaz, M., & Donato, N. J. (2018) · Neoplasia · doi:10.1016/j.neo.2017.11.007 · Cited by 39
Zheng, L., Yang, W., Zhang, C., Ding, W., Zhu, H., Lin, N.-M., Wu, H., He, Q., & Yang, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.05.011 · Cited by 41
Metadata
- Authors
- Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., Yue, P., Dornan, D., Huang, D. C. S., & Dixit, V. M.
- Affiliations
- Genentech (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Dixit, Vishva M.
- Venue
- Nature
- Published
- 2009-12-20
- Volume
- 463
- Issue
- 7277
- Pages
- 103-107
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1991249033
- Cited by
- 628
- References
- 31
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 21 · 2022: 20 · 2021: 38 · 2020: 41 · 2019: 44 · 2018: 45 · 2017: 45 · 2016: 51 · 2015: 49 · 2014: 50 · 2013: 46 · 2012: 44
- FWCI
- 15.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- USP9X, Mcl-1, deubiquitinase, protein stabilization, ubiquitination, multiple myeloma, Bcl-2 family proteins, apoptosis, ABT-737, BH3 mimetics, follicular lymphoma, diffuse large B-cell lymphoma, chemoresistance, therapeutic target, prognosis, proteasomal degradation, stem/progenitor cells, tumor cell survival
- MeSH terms
- Docetaxel, Animals, Biphenyl Compounds, Cell Line, Cell Survival, DNA Damage, Etoposide, Female, Half-Life, Humans, Lysine, Neoplasms, Nitrophenols, Phosphorylation, Piperazines, Prognosis, Protein Binding, Sulfonamides, Ultraviolet Rays, Gene Expression Regulation, Neoplastic, Mice, SCID, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Xenograft Model Antitumor Assays, Polyubiquitin, RNA Interference, Ubiquitin Thiolesterase, Taxoids, Cell Line, Tumor, Mice, Ubiquitination, Protein Stability, Gene Knockdown Techniques, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.